Osteoarthritis Knee Pain Relief | Synvisc-One® (Hylan G-F 20) | For HCPs

Time 2020-11-12 12:05:25

Web Name: Osteoarthritis Knee Pain Relief | Synvisc-One® (Hylan G-F 20) | For HCPs

WebSite: http://www.synvisconehcp.com

ID:113430

Keywords:

Relief,Synvisc,Pain,

Description:

This site is intended for US healthcare professionals onlyDo you wish to continue?This site is intended for U.S. Healthcare Professionals only.Do you wish to continue?for content, accuracy or completeness. Useof and access to this information is subject tothe terms, limitations and conditions set by thewebsite and/or database producer.This site might not comply with the regulatory requirements of US INDICATIONSYNVISC (hylan G-F 20) and Synvisc-One (hylan G-F 20) are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. SYNVISC and Synvisc-One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported for both SYNVISC and Synvisc-One.Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence. Do not inject SYNVISC or Synvisc-One extraarticularly, into the synovial tissues, into the fat pad or joint capsule, or intravascularly.The safety and efficacy of Synvisc-One in locations other than the knee, or for conditions other than osteoarthritis, or in combination with other intra-articular injectables, or in severely inflamed knee joints have not been established. Use caution when injecting SYNVISC or Synvisc-One in patients allergic to avian proteins, feathers, or egg products; who have evidence of lymphatic or venous stasis in the leg to be treated; or who have severe inflammation in the knee to be treated. Remove any synovial fluid or effusion before injecting SYNVISC or Synvisc-One. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC and Synvisc-One have not been established in children ( 21 years old) or in pregnant or lactating women. Patients should be advised to avoid strenuous or prolonged weight-bearing activities for approximately 48 hours after treatment.For SYNVISCIn clinical trials, the most commonly reported adverse events were transient pain, swelling, and or joint effusion in the injected knee. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.Full Prescribing Information for SYNVISCFor Synvisc-OneThe most commonly reported adverse events were arthralgia, arthritis, arthropathy, injection site pain, and joint effusion. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc-One: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.Full Prescribing Information for Synvisc-One SYNVISC and Synvisc-One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported for both SYNVISC and Synvisc-One.Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence. Do not inject SYNVISC or Synvisc-One extraarticularly, into the synovial tissues, into the fat pad or joint capsule, or intravascularly.The safety and efficacy of Synvisc-One in locations other than the knee, or for conditions other than osteoarthritis, or in combination with other intra-articular injectables, or in severely inflamed knee joints have not been established. Use caution when injecting SYNVISC or Synvisc-One in patients allergic to avian proteins, feathers, or egg products; who have evidence of lymphatic or venous stasis in the leg to be treated; or who have severe inflammation in the knee to be treated. Remove any synovial fluid or effusion before injecting SYNVISC or Synvisc-One. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC and Synvisc-One have not been established in children ( 21 years old) or in pregnant or lactating women. Patients should be advised to avoid strenuous or prolonged weight-bearing activities for approximately 48 hours after treatment.For SYNVISCIn clinical trials, the most commonly reported adverse events were transient pain, swelling, and or joint effusion in the injected knee. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.Full Prescribing Information for SYNVISCFor Synvisc-OneThe most commonly reported adverse events were arthralgia, arthritis, arthropathy, injection site pain, and joint effusion. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc-One: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.Full Prescribing Information for Synvisc-OneQuestions or Comments? Click here. This site is intended for U.S. Healthcare Professionals Only. Healthcare providers, enter your direct phone number and ZIP Code then hit "submit" to be connected to a Sanofi representative. There has been an error submitting your information. Please wait a moment and try again. Try Again You’ll be contacted momentarily. Be ready, a Sanofi representative will give you a call shortly. Please have the phone of the number you provided close by. Thank you for your interest. Close Available hours (excluding holidays): Monday-Friday 8 a.m.-7 p.m. ET Healthcare providers can connect with a Sanofi representative during available hours. Sanofi US respects your interest in keeping your personal information private. We will not sell or rent your information to any third parties. For more information on our use of information see our privacy policy. SAUS.HYL.18.11.6624

TAGS:Relief Synvisc Pain 

<<< Thank you for your visit >>>

Get information about the Synvisc-One® (Hylan G-F 20) injection. Help your patients relieve osteoarthritis knee pain for up to six months. Sign up to stay informed.

Hot Websites